background: androgen receptors (ar) play an important role in proliferation of cancerous prostatic cells and prevention of apoptotic signaling. current drugs cannot inhibit the activity of these receptors very well. establishment of appropriate animal models is essential for discovery of new drugs of target therapy in hormone dependent prostate cancer. materials and methods: standard prostatic ...

NEW DRUGS Cervical Cancer Vaccine The Food and Drug Administration (FDA) has approved Gardasil (Merck), the first vaccine developed to prevent cervical cancer, precancerous genital lesions, and genital warts caused by human papilloma virus (HPV) types 6, 11, 16, and 18 for females nine to 26 years of age. This agent was evaluated and approved in six months under the FDA’s priority review proces...

nanoparticles have been at the center of research focus as a new promising material for the treatment of cancer in recent years. although many chemotherapy drugs for cancer treatment are available, their potential toxicity is the main point of concern. on the other hand, the conventional chemotherapeutic approach has not been found to be very efficient in colorectal cancer (crc) as the drug mol...

BACKGROUND Gastric cancer is the second most common cause of cancer-related deaths worldwide. There are large geographic variations in the incidence of these tumors, with 60% occurring in East Asia. For patients with resectable disease, surgery and perioperative treatment can be effective. For patients with advanced gastric cancer, chemotherapy regimens result in a median survival of 9-11 month...

Recently there have been significant advances in rational drug design for the treatment of breast cancer, especially in the area of targeted drug therapy. These include drugs which target the HER2 receptor and angiogenesis and the novel class of drug the PARP inhibitors. Some of these agents, for example, trastuzumab used in the treatment of HER2 positive breast cancer are already established a...

The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...